NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis

Canada • TSX Venture Exchange • TSX-V:NSCI • CA63000Y1034

0.155 CAD
0 (0%)
Last: Feb 3, 2026, 07:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NSCI. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. NSCI may be in some trouble as it scores bad on both profitability and health. NSCI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NSCI had negative earnings in the past year.
  • In the past year NSCI had a positive cash flow from operations.
  • In the past 5 years NSCI always reported negative net income.
  • In the past 5 years NSCI reported 4 times negative operating cash flow.
NSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFNSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • NSCI has a better Return On Assets (-33.37%) than 87.50% of its industry peers.
  • Looking at the Return On Equity, with a value of -109.99%, NSCI belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
Industry RankSector Rank
ROA -33.37%
ROE -109.99%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
NSCI.CA Yearly ROA, ROE, ROICNSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • The Gross Margin of NSCI (26.96%) is worse than 68.75% of its industry peers.
  • NSCI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
NSCI.CA Yearly Profit, Operating, Gross MarginsNSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

3

2. Health

2.1 Basic Checks

  • NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NSCI has more shares outstanding
  • Compared to 5 years ago, NSCI has more shares outstanding
  • The debt/assets ratio for NSCI is higher compared to a year ago.
NSCI.CA Yearly Shares OutstandingNSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NSCI.CA Yearly Total Debt VS Total AssetsNSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • NSCI has an Altman-Z score of -0.89. This is a bad value and indicates that NSCI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NSCI (-0.89) is better than 75.00% of its industry peers.
  • NSCI has a debt to FCF ratio of 132.94. This is a negative value and a sign of low solvency as NSCI would need 132.94 years to pay back of all of its debts.
  • NSCI has a better Debt to FCF ratio (132.94) than 100.00% of its industry peers.
  • NSCI has a Debt/Equity ratio of 1.00. This is a neutral value indicating NSCI is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.00, NSCI is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 132.94
Altman-Z -0.89
ROIC/WACCN/A
WACC8.52%
NSCI.CA Yearly LT Debt VS Equity VS FCFNSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • NSCI has a Current Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NSCI's Current ratio of 0.86 is fine compared to the rest of the industry. NSCI outperforms 75.00% of its industry peers.
  • A Quick Ratio of 0.62 indicates that NSCI may have some problems paying its short term obligations.
  • NSCI has a better Quick ratio (0.62) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.62
NSCI.CA Yearly Current Assets VS Current LiabilitesNSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

  • The earnings per share for NSCI have decreased strongly by -36.84% in the last year.
  • The Revenue has decreased by -2.93% in the past year.
  • NSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.32% yearly.
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.21% on average over the next years. This is a very strong growth
  • NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.74% yearly.
EPS Next Y18.18%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue Next Year-3.67%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NSCI.CA Yearly Revenue VS EstimatesNSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
NSCI.CA Yearly EPS VS EstimatesNSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05 -0.1 -0.15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

  • NSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NSCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSCI.CA Price Earnings VS Forward Price EarningsNSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NSCI is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, NSCI is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 127.28
EV/EBITDA 120.65
NSCI.CA Per share dataNSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NSCI's earnings are expected to grow with 38.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.78%
EPS Next 3Y38.46%

More info and screens

0

5. Dividend

5.1 Amount

  • NSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NANALYSIS SCIENTIFIC CORP

TSX-V:NSCI (2/3/2026, 7:00:00 PM)

0.155

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-24
Earnings (Next)04-22
Inst Owners8.47%
Inst Owner ChangeN/A
Ins Owners3.93%
Ins Owner ChangeN/A
Market Cap17.95M
Revenue(TTM)41.74M
Net Income(TTM)-12.38M
Analysts80
Price Target0.64 (312.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.02%
Min Revenue beat(2)-14.08%
Max Revenue beat(2)-7.95%
Revenue beat(4)1
Avg Revenue beat(4)-5.27%
Min Revenue beat(4)-14.08%
Max Revenue beat(4)8.09%
Revenue beat(8)5
Avg Revenue beat(8)12.52%
Revenue beat(12)6
Avg Revenue beat(12)3.83%
Revenue beat(16)8
Avg Revenue beat(16)1.55%
PT rev (1m)0%
PT rev (3m)-24.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-63.64%
EPS NY rev (3m)-350%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF 127.28
P/OCF 9.6
P/B 1.59
P/tB N/A
EV/EBITDA 120.65
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0
FCFY0.79%
OCF(TTM)0.02
OCFY10.41%
SpS0.36
BVpS0.1
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.37%
ROE -109.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.96%
FCFM 0.34%
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 132.94
Debt/EBITDA 41.54
Cap/Depr 43.06%
Cap/Sales 4.14%
Interest Coverage N/A
Cash Conversion 692.22%
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.62
Altman-Z -0.89
F-Score5
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y18.18%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%
Revenue Next Year-3.67%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%
EBIT growth 1Y35.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.21%
EBIT Next 3Y70.03%
EBIT Next 5Y55.27%
FCF growth 1Y100.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.27%
OCF growth 3YN/A
OCF growth 5Y33.1%

NANALYSIS SCIENTIFIC CORP / NSCI.CA FAQ

What is the ChartMill fundamental rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NSCI.CA.


Can you provide the valuation status for NANALYSIS SCIENTIFIC CORP?

ChartMill assigns a valuation rating of 3 / 10 to NANALYSIS SCIENTIFIC CORP (NSCI.CA). This can be considered as Overvalued.


What is the profitability of NSCI stock?

NANALYSIS SCIENTIFIC CORP (NSCI.CA) has a profitability rating of 2 / 10.


What is the financial health of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

The financial health rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is 3 / 10.


What is the earnings growth outlook for NANALYSIS SCIENTIFIC CORP?

The Earnings per Share (EPS) of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is expected to grow by 18.18% in the next year.